Skip to content

ACADIA Pharmaceuticals

US · ACAD #2404 by market cap Listed 1970
19.65 -0.09 -0.46%
Live - 5344 symbols - heartbeat 314s ago · 2026-10-08 07:15
Pre-market 19.80 +0.75%
After-hours 19.70 +0.25%
Market cap
3.39B
P/B
2.59
EPS
2.30
Reader sentiment Are you bullish or bearish on ACAD?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Stifel Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Raises Target Price to $25
    Market Newswire · 2026/7/25
  • Rating change
    Morgan Stanley Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $26
    Market Newswire · 2026/8/5
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Kyverna Therapeutics, Inc. (KYTX)
    TipRanks · 2026/9/25
  • Rating change
    BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $31
    Market Newswire · 2026/8/5
  • Rating change
    Needham Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $41
    Market Newswire · 2026/8/12
  • Rating change
    Citi Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $39
    Market Newswire · 2026/8/10
  • CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $36
    Market Newswire · 2026/9/3
  • Rating change
    A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $38
    Market Newswire · 2026/8/5
  • Deutsche Bank Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38
    Market Newswire · 2026/8/25
  • A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $31 to $36
    Market Newswire · 2026/9/26
  • Rating change
    A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $40
    Market Newswire · 2026/8/25
  • Analysts' Top Healthcare Picks: Kyverna Therapeutics, Inc. (KYTX), ACADIA Pharmaceuticals (ACAD)
    TipRanks · 2026/9/25
  • Rating change
    UBS Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $49
    Market Newswire · 2026/8/17
  • Rating change
    BMO Capital Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $36
    Market Newswire · 2026/8/18
  • Rating change
    Mizuho Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/7/22
  • Rating change
    RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $37
    Market Newswire · 2026/8/5
  • Rating change
    UBS Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $49
    Market Newswire · 2026/8/18
  • Rating change
    BMO Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $36
    Market Newswire · 2026/7/22
  • Rating change
    H.C. Wainwright Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $37
    Market Newswire · 2026/7/31
  • RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $37
    Market Newswire · 2026/10/6

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:15:07 · For reference only, not investment advice and not tailored to your situation.